All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What is new in CAR T-cell therapy for pediatric acute lymphoblastic leukemia?
By Sabina Ray
Featured
Bookmark this article
During the European Society of Hematology (ESH) 2nd How I manage: CAR T therapies and bispecific antibodies for my patients 2023 Congress, the Lymphoma Hub spoke to André Baruchel, Hôpital Robert-Debré, Paris, FR. We asked, What is new in chimeric antigen receptor (CAR) T-cell therapy for pediatric acute lymphoblastic leukemia.
What is new in CAR T-cell therapy for pediatric acute lymphoblastic leukemia?
Baruchel discusses long-term results of clinical trials investigating CAR T-cell therapy and the benefits for pediatric patients with advanced acute lymphoblastic leukemia. He also mentions potential causes for relapse after CAR T-cell treatment and how new constructs could tackle this problem.
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox